Zominat

Zominat Uses, Dosage, Side Effects, Food Interaction and all others data.

Zominat is an antimigraine agent. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of Zominat for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Zominat is rapidly and well absorbed after oral administration.

Zominat, like other triptans, is a serotonin (5-hydroxytryptamine; 5-HT) receptor agonist, with enhanced specificity for the 5-HT1B and 5-HT1D receptor subtypes. It is through the downstream effects of 5-HT1B/1D activation that triptans are proposed to provide acute relief of migraines. Zominat is also a vasoconstrictor, leading to possible adverse cardiovascular effects such as myocardial ischemia/infarction, arrhythmias, cerebral and subarachnoid hemorrhage, stroke, gastrointestinal ischemia, and peripheral vasospastic reactions. In addition, chest/throat/neck/jaw pain, tightness, and/or pressure has been reported, along with the possibility of medication overuse headaches and serotonin syndrome. Patients with phenylketonuria should be advised that ZOMIG-ZMT contains phenylalanine.

Trade Name Zominat
Availability Prescription only
Generic Zolmitriptan
Zolmitriptan Other Names Zolmitriptan, Zolmitriptán, Zolmitriptanum
Related Drugs Nurtec ODT, Zomig, Tosymra, Ubrelvy, Botox, diclofenac, celecoxib, metoclopramide, sumatriptan, Imitrex
Weight 2.5mg
Type Tablet
Formula C16H21N3O2
Weight Average: 287.3568
Monoisotopic: 287.163376931
Protein binding

Zolmitriptan and its active N-desmethyl metabolite remain approximately 25% bound to plasma proteins over a concentration range of 10-1000 ng/mL.

Groups Approved, Investigational
Therapeutic Class 5-HT Agonists
Manufacturer Bio Pharma
Available Country Pakistan
Last Updated: September 19, 2023 at 7:00 am
Zominat
Zominat

Uses

Zominat is used for the treatment of acute migraine with or without aura in adults.

Zominat is also used to associated treatment for these conditions: Cluster Headache, Migraine

How Zominat works

Migraines are complex physiological events characterized by unilateral throbbing headaches combined with photophobia and other aversions to sensory input. Migraine attacks are generally divided into phases: the premonitory phase, which typically involves irritability, fatigue, yawning, and stiff neck; the headache phase, which lasts for between four and 72 hours; and the postdrome phase, which lasts for up to a day following resolution of pain and whose symptoms are similar to those of the premonitory phase. In addition, neurological deficits, collectively termed migraine aura, may precede the headache phase.

The underlying pathophysiology of migraines is a matter of active research but involves both neurological and vascular components. The head pain associated with migraine is thought to be a consequence of activation of the nociceptive nerves comprising the trigeminocervical complex (TCC). Terminals of nociceptive nerves that innervate the dura matter release vasoactive peptides, such as calcitonin gene-related peptide (CGRP), resulting in cranial vasodilation. Finally, when present, migraine aura appears to correlate with a transient wave(s) of cortical depolarization, termed cortical spreading depression (CSD).

Triptans, including zolmitriptan, are proposed to act in three ways. The main mechanism is through modulation of nociceptive nerve signalling in the central nervous system through 5-HT1B/1D receptors throughout the TCC and associated areas of the brain. In addition, triptans can enhance vasoconstriction, both through direct 5-HT1B-mediated dilation of cranial blood vessels, as well as through 5-HT1D-mediated suppression of CGRP release.

Although triptans are classically described solely in terms of their effects on 5-HT1B/1D receptors, they also act as 5-HT1F agonists as well. This 5-HT subtype is also found throughout the TCC, but is not present appreciably in cerebral vasculature; the significance of triptan-mediated 5-HT1F activation is currently not well described. Additionally, CSD that initiates in the ipsilateral parietal region may exert its effects in a manner that relies on 5-HT1B/1D receptor activation, suggesting that triptans may have some effect on CSD-mediated symptoms.

Dosage

Zominat dosage

The recommended dose of Zominat to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose has been shown to be effective, but it should not be taken within 2 hours of the initial dose. If a patient does not achieve satisfactory relief with 2.5 mg doses, subsequent attacks can be treated with 5 mg initial doses of Zominat. In those patients who respond, significant efficacy is apparent within 1 hour of dosing. Zominat is equally effective whenever the tablets are taken during a migraine attack, although it is advisable that Zominat tablets are taken as early as possible after the onset of migraine headache.Zominat is not indicated for prophylaxis of migraine. In the event of recurrent attacks, it is recommended that the total intake of Zominat in a 24 hour period should not exceed 10 mg.

Side Effects

Zominat is generally well tolerated. Adverse reactions are typically mild/moderate, transient, not serious and resolve spontaneously without additional treatment. Possible adverse reactions tend to occur within 4 hours of administration and are not more frequent following repeated dosing. The following adverse reactions have been the most commonly reported: nausea, dizziness, somnolence, warm sensation, asthenia and dry mouth. Abnormalities or disturbances of sensation have been reported, heaviness, tightness or pressure may occur in the throat, neck, limbs and chest (with no evidence of ischaemic changes on ECG) as may myalgia, muscle weakness, paraesthesia and dysesthesia.

Toxicity

Toxicity information regarding zolmitriptan is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as cardiovascular symptoms due to excessive vasoconstriction and activation of serotonergic receptors. Patients receiving a single 50 mg oral dose of zolmitriptan often experienced sedation. Symptomatic and supportive measures are recommended.

Precaution

Zominat should only be used where a clear diagnosis of migraine has been established. Care should be taken to exclude other potentially serious neurological conditions. There are no data on the use of Zominat in haemiplegic or basilar migraine. Zominat should not be given to patients with Wolff Parkinson White syndrome or arrhythmias associated with other accessory cardiac condition pathways. This class of compounds (5HT1D agonists) has been associated with coronary vasospasm; as a result, patients with ischaemic heart disease were excluded from clinical trials. Zominat is therefore, not recommended in this patient group. In patients in whom unrecognised coronary artery disease is likely, cardiovascular evaluation prior to commencement of treatment with 5HT1D agonists is recommended. As with other 5HT1D agonists, atypical sensations over the pericardium have been reported after the administration of Zominat, but in clinical trials these have not been associated with arrhythmias or ischaemic changes on ECG. Zominat may cause mild, transient increases in blood pressure (which may be more pronounced in the elderly), however this has not been associated with clinical sequelae in the clinical trial programme.

Interaction

From studies there is no evidence that concomitant use of migraine prophylactic medications (for example b blockers, oral dihydroergotamine, Pizotifen) has any effect on the efficacy or unwanted effects of Zominat. The pharmacokinetics and tolerability of Zominat oral tablets were unaffected by acute symptomatic treatments such as Paracetamol, Metoclopramide and Ergotamine. Concomitant administration of other 5HT1B/1D agonists within 12 hours of Zominat treatment should be avoided. Data from healthy subjects suggest that there are no pharmacokinetic or clinically significant interactions between Zominat and Ergotamine, however, the increased risk of coronary vasospasm is a theoretical possibility.Therefore, it is advised to wait at least 24 hours following the use of Ergotamine containing preparations before administering Zolmit. Conversely it is advised to wait at least six hours following use of Zominat before administering any Ergotamine preparation. A maximum intake of 5 mg Zominat nasal spray in 24 hours is recommended in patients taking an MAO inhibitor, general P450 inhibitor. Fluoxetine does not affect the pharmacokinetic parameters of Zominat. Therapeutic doses of the selective serotonin reuptake inhibitors (SSRIs), Fluoxetine, Sertraline, Paroxetine and Citalopram do not inhibit CYP1A2.

Food Interaction

  • Take with or without food. Food does not significantly impact the oral bioavalibility of zolmitriptan.

[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.

Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.

Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

Zominat Cholesterol interaction

[Major] The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.

Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).

Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.

In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.

As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.

Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

Volume of Distribution

Zominat has a volume of distribution between 7 and 8.4 L/kg.

Elimination Route

Zominat tablets have a mean absolute oral bioavailability of approximately 40%, with food having no effect on the rate or extent of absorption. The dosing kinetics are linear over a range of 2.5 to 50 mg with 75% of the eventual Cmax being attained within 1 hour of dosing. The median Tmax for the tablet form is 1.5 hours, while for the orally disintegrating tablet form, it is 3 hours. The AUC across studies was in the range of 84.4-173.8 ng/mL*h while the Cmax was between 16 and 25.2 ng/mL.

Zominat administered as a nasal spray is detected in the plasma within 2-5 minutes, compared to 10-15 minutes for the tablet form; the faster kinetics likely reflect fast absorption across the nasal mucosa. The bioavailability compared to the tablet is 102%, and plasma zolmitriptan concentration is maintained for 4-6 hours after intranasal delivery.

The active N-desmethyl metabolite of zolmitriptan has a mean plasma concentration that is roughly two-thirds of zolmitriptan, regardless of dosage route or concentration.

Half Life

Zominat has a mean elimination half-life of approximately three hours, while its active N-desmethyl metabolite has a slightly longer (approximately 3.5 hours) half-life.

Clearance

Zominat has a clearance of 31.5 mL/min/kg for oral tablets and 25.9 mL/min/kg for nasal administration; one-sixth of the clearance is renal.

Elimination Route

Zominat is primarily excreted in urine (approximately 65%) and feces (approximately 30%). Within urine, the most common form is the indole acetic acid metabolite (31%), followed by the N-oxide (7%), and N-desmethyl (4%) metabolites; the majority of zolmitriptan recovered in feces remains unchanged.

Pregnancy & Breastfeeding use

Pregnancy: Zominat should be used in pregnancy only if the benefits to the mother justify potential risk to the foetus.Lactation: Studies have shown that Zominat passes into the milk of lactating animals. No data exist in lactating women. Therefore, caution should be exercised when administering Zominat to lactating women.

Contraindication

Zominat is contraindicated in patients with :

  • Known hypersensitivity to any component of the product
  • Uncontrolled hypertension
  • Ischaemic heart disease
  • Coronary vasospasm/Prinzmetal’s angina
  • A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)

Special Warning

Use in children: Safety and efficacy of Zominat in paediatric patients have not been established.Use in patients aged over 65 years: Safety and efficacy of Zominat in individuals aged over 65 years have not been systematically evaluated.Patients with hepatic impairment: The dose of Zominat should be reduced in patients with moderate to severe hepatic impairment, maximum dose of 5 mg in 24 hours is recommended. Patients with renal impairment: No dosage adjustment is required.

Storage Condition

Keep out of the reach of children. Store at a cool and dry place. Protect from light and moisture.

Innovators Monograph

You find simplified version here Zominat

Zominat contains Zolmitriptan see full prescribing information from innovator Zominat Monograph, Zominat MSDS, Zominat FDA label

FAQ

What is Zominat prescribed for?

Zominat is prescribe to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light).

How fast does Zominat work?

People with migraine want treatment that eliminates the headache and any associated symptoms quickly (maximum two hours) and prevents it returning (within 24 hours). Results indicate that with the 5 mg dose only 14% of those treated were pain-free at 2 hours with no headache recurrence within 24 hours.

How strong is Zominat?

The recommended starting dose of Zominat is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of Zominat is 5 mg.

Is Zominat a pain killer?

Zominat is used to treat headache pain during a migraine attack, not to stop the pain from coming on. You should wait until the migraine symptoms start to develop, rather than taking it when you feel that a migraine may be developing.

What type of drug is Zominat?

Zominat is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels around the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine.

Can I take Zominat every day?

Since Zominat is used as needed, it does not have a daily dosing schedule. Call your doctor promptly if your symptoms do not improve after using Zominat.

How often can I take Zominat?

If you feel much better after a dose of Zominat, but your headache comes back or gets worse after a while, you may use one additional dose of Zominat 2 hours after the first dose. Do not use more than 2 doses in any 24-hour period.

What happens if I take too much Zominat?

Call your doctor right away if you have any of the following problems after taking Zominat: severe tightness, pain, pressure or heaviness in your chest, throat, neck, or jaw. shortness of breath or wheezing. sudden or severe stomach pain.

Is it safe to take Zominat?

Zominat has caused serious side effects in some people, especially people who have heart or blood vessel disease. Be sure that you discuss with your doctor the risks of using this medicine as well as the benefits that it can do.

Can I take Zominat without food?

Take this medication by mouth with or without food as directed by your doctor, at the first sign of a migraine.

How does Zominat work?

Zominat is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels around the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine.

Can I drink alcohol with Zominat?

Alcohol can increase the nervous system side effects of Zominat such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with Zominat.

Does Zominat raise blood pressure?

Zominat can raise blood pressure to dangerous levels. Your blood pressure may need to be checked often while you are using this medicine. Your heart function may need to be checked using an electrocardiograph or ECG (sometimes called an EKG)

What are the side effects of Zominat?

Zominat may cause side effects.

  • feeling warm or cold.
  • drowsiness.
  • dry mouth.
  • nausea.
  • heartburn.
  • sweating.
  • dizziness or faintness




How does Zominat make me feel?

Some people feel drowsy or dizzy during or after a migraine, or after taking Zominat to relieve a migraine. As long as you are feeling drowsy or dizzy, do not drive, use machines, or do anything else that could be dangerous until you know how this medicine affects you.

What can I take with Zominat?

Do not take other migraine treatments (such as other triptans or ergotamine) at the same time as Zominat. Some people may benefit from taking a non-steroidal anti-inflammatory painkiller (such as naproxen) in addition to Zominat. Your doctor will advise you about this if it is recommended for you.

How long does Zominat last?

People with migraine want treatment that eliminates the headache and any associated symptoms quickly (maximum two hours) and prevents it returning (within 24 hours). Results indicate that with the 5 mg dose only 14% of those treated were pain-free at 2 hours with no headache recurrence within 24 hours.

How many Zominat can I take in a day?

Adults 2.5 mg placed on top of your tongue. If the migraine comes back after being relieved, another dose may be taken if at least 2 have passed since the first dose. Do not take more than 5 mg in a single dose or 10 mg in any 24-hour period. 

Can I overdose on Zominat?

Zominat should not take overdose.

Can I take Zominat with Tylenol?

No interactions were found between Tylenol and Zominat. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Is Zominat a controlled substance?

Zominat is used in the treatment of migraine and belongs to the drug class antimigraine agents. Risk cannot be ruled out during pregnancy. Brand 5 mg is not a controlled substance under the Controlled Substances Act (CSA).

What does Zominat do to the brain?

It works by narrowing blood vessels around the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine.

Can I get addicted to Zominat?

Short answer is no.

How safe is Zominat?

Zominat has caused serious side effects in some people, especially people who have heart or blood vessel disease. Be sure that you discuss with your doctor the risks of using this medicine as well as the benefits that it can do.

Is Zominat safe during pregnancy?

doctors advise against taking these type of Zominat during pregnancy. Zominat carry a risk of birth defects, especially if taken in the first trimester.

Is Zominat safe during breastfeeding?

Zominat ingested by the infant are small and unlikely to affect the nursing infant, especially if the infant is older than 2 months.

*** Taking medicines without doctor's advice can cause long-term problems.
Share